Compare CEPU & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CEPU | SUPN |
|---|---|---|
| Founded | 1989 | 2005 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 2017 | 2010 |
| Metric | CEPU | SUPN |
|---|---|---|
| Price | $16.73 | $51.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $17.50 | ★ $61.60 |
| AVG Volume (30 Days) | 414.1K | ★ 474.4K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $10.11 | $22.72 |
| Revenue Next Year | N/A | $18.10 |
| P/E Ratio | $12.24 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.43 | $29.16 |
| 52 Week High | $18.50 | $59.68 |
| Indicator | CEPU | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 53.28 |
| Support Level | $14.84 | $47.43 |
| Resistance Level | $18.22 | $52.14 |
| Average True Range (ATR) | 0.79 | 1.62 |
| MACD | 0.17 | 0.18 |
| Stochastic Oscillator | 79.53 | 81.02 |
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.